<DOC>
	<DOCNO>NCT02217345</DOCNO>
	<brief_summary>Nonalcoholic fatty liver disease ( NAFLD ) , fatty infiltration liver absence alcohol use , increasingly recognize complication obesity , prevalence estimate 30 % individual United States . A subset develop progressive disease form nonalcoholic steatohepatitis ( NASH ) , progress cirrhosis liver failure . NAFLD expect common indication liver transplantation year 2020 . We hypothesize growth hormone ( GH ) replacement decrease intrahepatic lipid accumulation quantify 1H magnetic resonance spectroscopy ( 1H-MRS ) .</brief_summary>
	<brief_title>Growth Hormone Intrahepatic Lipid Content Patients With Nonalcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Ages 18 65 yr 2 . NAFLD define demonstration hepatic steatosis image biopsy absence significant alcohol consumption cause hepatic steatosis . If liver imaging biopsy perform clinically , liver ultrasound perform part screen visit . 1 . Serum creatinine &gt; 2 time upper limit normal 2 . History cancer , except nonmelanoma skin cancer 3 . Active carpel tunnel syndrome 4 . Diabetes mellitus , define hemoglobin A1C &gt; 6.5 use medication prescribe treat hyperglycemia . 5 . Contraindications magnetic resonance imaging ( MRI ) . 6 . Pregnancy desire become pregnant . Participants reproductive age must agree use contraception . 7 . Breastfeeding 8 . Aspartate aminotransferase level &gt; 5x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>